References
- 1. M. Polakovicova and R. Cizmarikova, Molecular docking study on the binding mode of cardioselective phenoxyaminopropanol blocker into b-adrenergic receptor subtypes, Acta Fac. Pharm. Univ. Comenianae 59 (2012) 44-53.
- 2. I. Malik, R. Govender, E. Sedlarova, J. Csollei, J. Jampilek, A. Coffey, J. O´Mahony and L. Stanzel, The in vitro investigation of ortho-/meta-/para alkoxyphenylcarbamic acid esters containing substitued N-phenylpiperazin-1-yl fragment against Mycobacterium tuberculosis H37Ra strain, Microbiol. Biotech. Food Sci. 3 (2014) 395-397.
- 3. K. Bruchata and R. Cizmarikova, New derivatives of aryloxyaminopropanol-structure biological activity relationship, Farm. Obzor 79 (2010) 287-293.
- 4. D. P. Jindal, M. S. Coumara, G. Brunib and P. Massarelli, Synthesis and b1-, b2-adrenergic receptor binding studies of 4-acylamino-substituted phenoxypropanolamine and 5-acylamino-substitut- ed naphthyloxypropanolamine derivatives, Arzneim-Forsch/Drug Res. 52 (2002) 654-663; https://doi.org/10.1055/s-0031-1299947
- 5. V. Cecchetti, F. Schiaffella, O. Tabarrini and A. Fravolini, (1,4-Benzothiazinyloxy) alkoxylpiperazine derivatives as potential antihypertensive agents, Bioorg. Med. Chem. Lett. 10 (2000) 465-468.
- 6. E. Racanska, I. Tumova and T. Foltanova, 2-, and 4-flurophenylpiperazine derivatives of alkoxyphenylcarbamic acid and their potential antidysrhytmic effect, Farm. Obzor 74 (2005) 247- 250.
- 7. C. V. Ram, Beta-blockers in hypertension, Am. J. Cardiol. 106 ( 2010) 1 819-1825; https://doi.org/10.1016/j.amjcard.2010.08.023
- 8. W. R. Chen, X. M. Shi, T. S. Yang, L. C. Zhao and L. G. Gao, Protective effect of metoprolol on arrhythmia and heart rate variability in healthy people with 24 hours of sleep deprivation, J. Interv. Card. Electrophysiol. 36 (2013) 267-272; https://doi.org/10.1007/s10840-012-9728-8
- 9. I. Malik, E. Sedlarova, J. Csöllei, E. Racanska, J. Cizmarik and P. Kurfürst, Synthesis, physicochemical properties and biological activity of 1-(4-fluorophenvl)-4-[3-(2-,3- and 4-alkyloxyphenylcarbamoyloxy)-2-hydroxypropyl] piperaziniumchlorides, Sci. Pharm. 72 (2004) 283-291; https://doi:10.3797/scipharm.aut-04-24
- 10. I. Malik, E. Sedlarova, J. Cizmarik, F. Andriamainty and J. Csollei, Study of physicochemical properties of 4-alkoxy-phenylcarbamic acid derivatives with various substituted N-phenylpiperazin-1-yl moiety in the basic part of the molecule, Farm. Obzor 74 (2005) 211-215.
- 11. E. Racanska, M. Maruniak, I. Tumova and E. Sedlarova, In vitro pharmacological evaluation of new phenylpiperazine derivatives of phenylcarbamic acid on their basic cardiovascular functions, Acta Facult. Pharm. Univ. Comenianae 57 (2010) 68-76.
- 12. E. Kráľová, T. Mokráň, J. Murín and T. Stankovičová, Electrocardiography in two models of isoproterenol- induced left ventricular remodelling, Physiol. Res. 57 (Suppl. 2) (2008) S83-S89.
- 13. J. Kmecova and J. Klimas, Heart rate correction of the QT duration in rats, Eur. J. Pharmacol. 641 (2010) 187-192; https://doi.org/10.1016/j.ejphar.2010.05.038
- 14. M. Kobayashi, N. Machida, R. Tanaka and Y. Yamane, Effects of b-blocker on left ventricular remodeling in rats with volume overload cardiac failure, J. Vet. Med. Sci. 70 (2008) 1231-1237.
- 15. Ch. Baillard, P. Mansier, P. V. Ennezat, L. Mangin, C. Medigue, B. Swynghedaw and B.Chevalier, Converting enzyme inhibition normalizes QT interval in spontaneously hypertensive rats, Hypertension 36 (2000) 350-354; https://doi.org/10.1161/01.HYP.36.3.350